PFE240802P18000
- 0.03
- 0.000.00%
Pfizer Newsroom
Pfizer Price Target Maintained With a $45.00/Share by Cantor Fitzgerald
Pfizer Price Target Raised to $31.00/Share From $30.00 by UBS
Pfizer Analyst Ratings
DZ BANK AG Maintains Pfizer(PFE.US) With Buy Rating
BofA Securities Maintains Pfizer(PFE.US) With Hold Rating
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $32 to $45
Cantor Fitzgerald Sticks to Its Buy Rating for Pfizer (PFE)
Truist Financial Keeps Their Buy Rating on Pfizer (PFE)
Morgan Stanley Raises Price Target on Pfizer to $31 From $29, Keeps Equalweight Rating
Pfizer Hold Rating Maintained Amid Growth Challenges and Valuation Concerns
Barclays Remains a Hold on Pfizer (PFE)
Jefferies Adjusts Price Target on Pfizer to $35 From $34, Keeps Buy Rating
J.P. Morgan Sticks to Its Hold Rating for Pfizer (PFE)
Buy Rating Affirmed: Sangamo's Hemophilia A Gene Therapy Poised for Success With Pfizer Partnership
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Pfizer's Mixed Outlook: Hold Rating Amidst Vyndaqel's Growth and Falling Demand for Comirnaty and Paxlovid
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Corcept Therapeutics (CORT) and Pfizer (PFE)
Analysts' Opinions Are Mixed on These Healthcare Stocks: KalVista Pharmaceuticals (KALV), Roche Holding AG (OtherRHHVF) and Pfizer (PFE)
Hold Rating on Pfizer: Caution Advised Amid Uncertainties Surrounding Danuglipron
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Pfizer (PFE)